The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nonomura, Y.
Right arrow Articles by Miyasaka, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nonomura, Y.
Right arrow Articles by Miyasaka, N.
The Journal of Immunology, 2003, 171: 4913-4919.
Copyright © 2003 by The American Association of Immunologists

Gene Transfer of a Cell Cycle Modulator Exerts Anti-Inflammatory Effects in the Treatment of Arthritis 1

Yoshinori Nonomura, Hitoshi Kohsaka2, Kenji Nagasaka and Nobuyuki Miyasaka

Department of Bioregulatory Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Forced expression of a cyclin-dependent kinase inhibitor gene, p21Cip1 in the synovial tissues was effective in treating animal models of rheumatoid arthritis. Synovial hyperplasia in the treated joints was suppressed, reflecting the inhibitory effect of p21Cip1 on cell cycle progression. Additionally, lymphocyte infiltration, expression of inflammatory cytokines, and destruction of the bone and cartilage were inhibited. To determine why the cell cycle regulator gene exerted such anti-inflammatory effects, we investigated gene expression by rheumatoid synovial fibroblasts with or without the p21Cip1 gene transferred. We have found that p21Cip1 gene transfer down-regulates expression of various inflammatory mediators and tissue-degrading proteinases that are critically involved in the pathology of rheumatoid arthritis. These molecules included IL-6, -8, type I IL-1R (IL-1R1), monocyte chemoattractant protein-1, macrophage inflammatory protein-3{alpha}, cathepsins B and K, and matrix metalloproteinases-1 and -3. Down-regulation of IL-1R1 by p21Cip1 resulted in attenuated responsiveness to IL-1. Inhibition of the inflammatory gene expression by p21Cip1 was seen even when IL-1 is absent. This IL-1R1-independent suppression was accompanied by reduced activity of c-Jun N-terminal kinase, which was associated with p21Cip1, and inactivation of NF-{kappa}B and AP-1. These multiple regulatory effects should work in concert with the primary effect of inhibiting cell cycle in ameliorating the arthritis, and suggest a heretofore unexplored relationship between cyclin-dependent kinase inhibitor gene and inflammatory molecules.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Synovial tissue from healthy individuals consists of a single layer of synovial cells without infiltration of inflammatory cells. In rheumatoid synovial tissue, lymphocytes and macrophages are recruited and activated, and these activated macrophages release high concentrations of inflammatory cytokines. In response to these cytokines, synovial fibroblasts proliferate vigorously and form villous hyperplastic synovial tissues. These fibroblasts secrete inflammatory mediators, which further attract inflammatory cells and stimulate growth of the synovial fibroblasts as well as that of vascular endothelial cells (1). These activated macrophages and fibroblasts produce tissue-degrading proteinases (2). Thus, the invasive hyperplastic synovial tissue, termed pannus, is directly responsible for structural and functional damage of the affected joints.

Therapeutic intervention against rheumatoid arthritis (RA) 3 could be aimed at any one of these steps. Recently developed biological reagents that block activities of TNF-{alpha} have proved to be beneficial in clinical settings. However, they and other conventional drugs do not necessarily control synovial inflammation and hyperplasia in all patients. We hypothesized that the proliferation of the synovial fibroblasts is a common outcome of the multiple inflammatory processes in RA. If synovial fibroblasts become refractory to the proliferative stimuli, the tissue-degrading pannus should not develop. This idea led us to explore new therapeutic approaches that directly control synovial cell proliferation (3, 4, 5). The molecules we have focused on are cyclin-dependent kinase inhibitors (CDKIs). These intracellular proteins inhibit kinase activity of cyclin/cyclin-dependent kinase (CDK) complexes that are required for cell cycle progression (6).

Our previous studies have shown that CDKIs p16INK4a and p21Cip1 are not expressed in vivo in the rheumatoid synovial tissues, but readily induced in vitro in cultured rheumatoid synovial fibroblasts (RSF). Induction of p16INK4a is characteristic of RSF (3). In vitro inducibility of p16INK4a and p21Cip1 suggested to us that their induction in vivo in the rheumatoid joints could be an ideal approach to suppression of the proliferative synovitis. This was substantiated by intraarticular transfer of the p16INK4a or p21Cip1 gene to rodent models of RA (4, 5). These gene therapies suppressed synovial hyperplasia and also inhibited lymphocyte infiltration and destruction of the bone and cartilage of the treated joints. Expression of inflammatory cytokines such as IL-1, -6 and TNF-{alpha} was suppressed even in the small amount of hyperplastic synovial tissues that remained after the gene transfer (4). These data argued that induction of CDKI ameliorated the arthritis not only by inhibition of cell cycle but by other unknown functions that suppressed the inflammatory network in the arthritic joint.

Unlike the other CDKIs, p21Cip1 binds to various molecules related to gene expression and exerts differential effects on different cells (7). However, little is known about the effects of p21Cip1 on gene expression in the inflamed tissues. We show here that up-regulated expression of the p21Cip1 gene in RSF suppresses expression of various inflammatory molecules that play critical roles in the pathology of RA. Manipulation of these multiple molecular events should contribute to the therapeutic effects of p21Cip1 gene therapy.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell culture and recombinant adenoviruses

Synovial tissues were obtained from patients who had responded poorly to anti-rheumatic drugs and underwent joint replacement or synovectomy for active rheumatoid synovitis at Tokyo Medical and Dental University Hospital (Tokyo, Japan), Tokyo Metropolitan Bokuto, or Fuchu Hospital (Tokyo, Japan). The patients fulfilled the American College of Rheumatology criteria for classification of RA (8). All patients gave their consent for all procedures in the present studies, which were also approved by the ethics committee of Tokyo Medical and Dental University. From villous and congestive synovial tissues, RSF were isolated and cultured as described elsewhere (3). They were used at passages 3–11. RSF were infected with AxCAp21 adenovirus, containing a human p21Cip1 gene (5, 9), or Ax1w1 adenovirus (Riken Gene Bank, Saitama, Japan), which lacks insert genes, at 50 multiplicity of infection. Some RSF were stimulated by 5 ng/ml TNF-{alpha} (Genzyme, Cambridge, MA), 5 ng/ml IL-1{beta} (PeproTech, Rocky Hill, NJ), and 25 µM indomethacin (Sigma-Aldrich, St. Louis, MO). In preliminary experiments, 5 ng/ml was determined to be the optimal concentration for each cytokine to stimulate RSF. RNeasy kit (Qiagen, Valencia, CA) with DNase I treatment was used to isolate total RNA. For ELISA, the virus-infected RSF were cultured for three days, transferred to microwells at 1.0 x 105 cells/ml, and incubated for 12 h. After replacement of the culture medium, RSF were further cultured for 24 h with 10% serum alone, 5 ng/ml IL-1{beta} together with 25 µM indomethacin, 5 ng/ml TNF-{alpha}, a combination of IL-1{beta}, indomethacin, and TNF-{alpha}, or 5 µg/ml LPS of Escherichia coli O55:B5 (Sigma-Aldrich). One hundred ng/ml IL-1R antagonist (IL-1ra) (R&D Systems, Mckinley, MN), which was sufficient for the inhibition of 10 pg/ml IL-1{beta}, was added to some wells. The culture supernatants were collected after 24 h. For Western blotting, RSF were lyzed for protein extraction at three days after the adenoviral infection (3). To assess transcription factor and c-Jun N-terminal kinase (JNK) activities in RSF that were incubated for 30 min in the medium containing 10% FBS with or without supplementation of 5 µg/ml LPS, nuclear extracts and cell lysates were prepared using Nuclear Extract Kit (Active Motif, Carlsbad, CA) or SAPK/JNK assay kit (Cell Signaling, Beverly, MA). The effects of the p21Cip1 gene were studied at three days after the adenoviral infection.

Northern blot analyses

Northern blotting was conducted as described elsewhere (10). Human monocyte chemoattractant protein (MCP)-1 cDNA (No. 65933, American Type Culture Collection, Manassas, VA), human GAPDH cDNA (Life Technologies, Rockville, MD), and PCR products of type I IL-1R (IL-1R1), cathepsins B and K, and matrix metalloproteinases (MMP)-1 and -3 were used as probes. Fragments of IL-1R1, cathepsins B and K, and MMPs-1 and -3 cDNA were generated with RT-PCR using cDNA derived from RSF. PCR was conducted with Taq polymerase (Life Technologies) and sets of specific primers: human IL-1R1-specific primers (11), human MMP-1-specific primers (12), human MMP-3-specific primers (12), human cathepsin B-specific primers (5'-TAG GAT CTG GCT TCC AAC AT-3' (sense) and 5'-CCA CGG CAG ATT AGA TCT TT-3' (antisense)) and human cathepsin K-specific primers (5'-AAC GAA GCC AGA CAA CAG ATT TCC-3' (sense), 5'-GAT TTG GCT GGC TGG AGT CAC A-3' (antisense)). Annealing temperatures were 58°C for IL-1R1, and cathepsins B and K cDNA, and 60°C for MMP-1 and -3 cDNA. The products were purified and labeled with [{alpha}-32P]dATP (Amersham Biosciences, Buckinghamshire, UK) and hybridized with the Northern blot membranes. Digital image files were generated with Phosphorimaging Screens and the BAS-2500 PhosphoImager, and analyzed with MacBAS 2.5.2 Software (Fuji Film, Kanagawa, Japan).

Western blot analyses and immunoprecipitation

Rabbit anti-human IL-1R1 Abs, rabbit anti-human Toll-like receptor (TLR)-4 Abs, and rabbit anti-human p21Cip1 Abs (sc-688, sc-10741 and sc-387, respectively, Santa Cruz Biotechnology, Santa Cruz, CA) were used as primary Abs for Western blot analyses. HRP-conjugated anti-rabbit IgG polyclonal Abs (NA-934, Amersham Biosciences) were used as the secondary Abs. Bound Abs were visualized with ECL or ECL-plus (Amersham Biosciences). Signal intensities were quantified with NIH Image ver. 1.62 (National Institutes of Health, Bethesda, MD). JNKs 1–3 were immunoprecipitated using mouse anti-human JNK2 Ab (sc-7345, Santa Cruz Biotechnology) (13).

ELISA

ELISA kits for IL-1{beta}, IL-6, IL-8, MCP-1, TNF-{alpha} (BioSource International, Camarillo, CA), IL-1{alpha}, macrophage inflammatory protein (MIP)-3{alpha} (R&D Systems), MMP-1 (Amersham Biosciences) and MMP-3 (Fuji Chemical, Toyama, Japan) were used to quantify the protein levels in the culture supernatants.

Multiwell colorimetric transcription factor assays and JNK kinase assay

Using Trans AM AP-1/c-Jun, NF-{kappa}Bp50, and p65 Transcription Factor Assay Kits (Active Motif), the nuclear extracts of RSF were examined for DNA binding activities of AP-1 and NF-{kappa}B (14). SAPK/JNK Assay Kit (Cell Signaling) was used to examine whole cell lysates for their JNK kinase activities to phosphorylate c-Jun substrates. The amount of the c-Jun substrate was standardized by immunoblotting with anti c-Jun Ab (sc-44, Santa Cruz Biotechnology).

Statistics

Signal intensity ratios of Northern and Western blot analyses, and protein concentrations were compared with a paired Student’s t test using StatView-5.0J software (SAS Institute, Cary, NC).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
p21Cip1 suppresses IL-1R1 and IL-6 expression by RSF

RSF samples derived from rheumatoid joints were cultured in vitro. Expression of p21Cip1 was not detected in any of the samples. They were infected with the AxCAp21 adenoviruses or the Ax1w1 adenoviruses. At three days postinfection, when the AxCAp21-infecrted RSF express p21Cip1 at the highest level, the cells were harvested for RNA and protein extraction.

In preliminary experiments using a few RSF samples and commercial DNA array systems, MCP-1, IL-1R1, and cathepsins B and K genes, which are related to RA pathology, showed a tendency to be down-regulated by the p21Cip1 gene transfer. Indeed, Northern blot analysis revealed that the IL-1R1 mRNA expression was significantly reduced in RSF overexpressing p21Cip1, compared with those infected with the control adenoviruses (Fig. 1A). Reflecting this, Western blot analyses of the total cell lysates showed that the IL-1R1 protein expression was reduced in the RSF expressing p21Cip1 (Fig. 1B).



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 1. Suppression of inflammatory cytokine and cytokine receptor expression by p21Cip1. A, RNA from the p21Cip1 adenovirus-infected (p21) and control adenovirus-infected RSF (control) were examined for IL-1R1 and GAPDH mRNA expression by Northern blot analysis. Representative blots of one of three samples are shown in the upper panel. Signal intensities of IL-1R1 were normalized with those of GAPDH (relative mRNA levels), and are shown in the lower panel. The columns and bars represent the mean and SD of three samples. Mean reduction by p21Cip1 was 48.2%. Statistical evaluation was conducted by paired Student’s t test. *, p < 0.05. B, The cells from the same donor were examined for IL-1R1 and CDK4 protein expression by Western blot analysis. Representative blots of one of three samples are shown in the upper panel. Signal intensities of IL-1R1 protein were normalized with those of constitutively expressed CDK4 (relative protein levels), and are shown in the lower panel. Mean reduction of expression by p21Cip1 was 67.6%. **, p < 0.01. C, RSF infected with the p21Cip1 adenoviruses (open columns), and infected with the control adenoviruses (solid columns) were cultured without stimulation (-) or stimulated with IL-1{beta} (IL-1), TNF-{alpha} (TNF), or combination of IL-1{beta} and TNF-{alpha} (IL-1+TNF) for 24 h. RSF were stimulated with LPS for 24 h in a separate set of experiments, where some RSF were treated with IL-1ra after the infection with the control adenoviruses (hatched column) or with the p21 adenoviruses (dotted column). IL-6 in the culture supernatants was measured by ELISA. Representative data of three independent experiments are shown. Columns and bars show the mean and SD of triplicate cultures. Mean reduction of expression by p21Cip1 in IL-1, IL-1+TNF, LPS, and LPS+IL-1ra were 77.4, 64.3, 69.4, and 64.3%, respectively. *, p < 0.05 and ***, p < 0.005. D, RSF infected with the p21Cip1 adenoviruses (open columns), and infected with the control adenoviruses (solid columns) and noninfected RSF (gray column) were cultured without stimulation (-) or stimulated with IL-1{beta} (IL-1) or TNF-{alpha} (TNF) for 24 h. IL-6 in the culture supernatants was measured by ELISA. Representative data of two experiments are shown. Columns and bars show the mean and SD of triplicate cultures. No statistical differences were found between IL-6 production by control-virus infected RSF and that by non-infected RSF. E, Expression of TLR4 and CDK4 proteins was analyzed by Western blot analysis. Representative blots of one of three samples are shown. The relative protein levels of TLR4 to CDK4 are shown as columns and bars. TLR4 protein level was not suppressed by p21Cip1.

 
The DNA array analyses suggested no differential expression of IL-6 in the unstimulated RSF. However, when RSF were stimulated by TNF-{alpha} and IL-1{beta} before the DNA array analysis, IL-6, as well as IL-8, MCP-1, MIP-3{alpha}, MMP-1, MMP-3, and cathepsin K genes showed a tendency to be down regulated by p21Cip1. This was consistent with the fact that TNF-{alpha} and IL-1, both of which are critically involved in activating RSF in the rheumatoid joints, stimulate RSF to promote secretion of various cytokines including IL-6 (15). The unstimulated RSF did not release IL-1{alpha}, IL-1{beta}, or TNF-{alpha} above the lowest limit of detection in the ELISA (3.9 pg/ml). These facts implied that the suppression of IL-6 in the stimulated RSF could be attributable to the down-regulation of IL-1R1. To address this issue, RSF were stimulated independently with IL-1{beta}, TNF-{alpha}, or a combination of the two. The culture supernatants were examined for the IL-6 concentration with ELISA. Each stimulation promoted IL-6 production. The effects of IL-1{beta} were suppressed significantly by p21Cip1 while the effects of TNF-{alpha} were not attenuated (Fig. 1C). Effects of the adenoviral infection alone on the IL-6 secretion were minimal (Fig. 1D). Thus, the down-regulation of IL-1R1 was biologically relevant to the suppression of IL-6.

To determine whether other pathways that regulate IL-6 production are affected, RSF were stimulated with LPS. Western blot analysis confirmed that Toll-like receptor (TLR)4, which is a receptor for LPS, was not down-regulated by p21Cip1 (Fig. 1E). Nevertheless, the p21Cip1 expression suppressed the IL-6 production that was induced by LPS (Fig. 1C). Again, the culture supernatants of the LPS-stimulated RSF did not contain detectable amounts of IL-1 (<3.9 pg/ml) or TNF-{alpha} (<1.7 pg/ml). To eliminate the effect of a trace amount of IL-1 that might possibly have been secreted with the LPS stimulation, 100 ng/ml IL-1ra, a competitive inhibitor of IL-1{alpha} and IL-1{beta}, was added to the culture. This treatment did not alter the results whereas the same concentration of IL-1ra suppressed the IL-6 production by RSF that were stimulated with 10 pg/ml IL-1{beta} (data not shown).

p21Cip1 suppresses inflammatory chemokine expression by RSF

The p21Cip1-induced reduction of the MCP-1 mRNA expression by unstimulated RSF was elucidated by Northern blot analyses (Fig. 2A). This was reflected in the reduced MCP-1 concentration in the culture supernatants of the p21Cip1-expressing RSF. As was the case in the IL-6 expression, addition of IL-1ra did not alter the results (Fig. 2B).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 2. Suppression of inflammatory chemokine expression by p21Cip1. A, The AxCAp21 adenovirus-infected (p21) and control adenovirus-infected (control) RSF from three RA patients were examined for MCP-1 mRNA expression by Northern blot analysis. RSF were not stimulated with cytokines. Representative results of one of three samples are shown in the upper panel. Signal intensities of MCP-1 messages normalized with those of GAPDH messages (relative mRNA levels) are shown as columns and bars, representing the mean and SD. Mean reduction of expression by p21Cip1 was 57.0%. *, p < 0.05. B, RSF with or without p21Cip1 expression (p21 and control) were cultured without cytokine stimulation. The culture medium was supplemented with FBS alone (solid columns) or with FBS plus IL-1ra (hatched columns). MCP-1 in the culture supernatants was measured by ELISA. Representative data of two experiments are shown. Columns and bars show the mean and SD of triplicate cultures. Mean reduction of expression by p21Cip1 was 83.8% (no IL-1ra) and 87.1% (IL-1ra). **, p < 0.01 and ***, p < 0.005. C-E, RSF infected with the p21Cip1 adenoviruses (open columns) or control adenoviruses (solid columns) were cultured without stimulation (-) or stimulated with IL-1{beta} (IL-1), TNF-{alpha} (TNF), a combination of IL-1{beta} and TNF-{alpha} (IL-1+TNF), or LPS for 24 h. Some RSF infected with the control adenoviruses (hatched column), and with the p21 adenoviruses (dotted column) were treated with IL-1ra before LPS stimulation. MCP-1 (C), MIP-3{alpha} (D), and IL-8 (E) in the culture supernatants were measured by ELISA. Representative data of two or three experiments are shown. Columns and bars show the mean and SD of triplicate cultures. n. d., not detectable. Mean reduction in expression of MCP-1 by p21Cip1 in IL-1, IL-1+TNF, LPS, and LPS + IL-1ra was 58.3, 57.5%, 84.7, and 83.9%, respectively. Mean reduction in expression of IL-8 by p21Cip1 in IL-1, IL-1+TNF, and LPS was 48.4, 38.2, and 54.0% and that of MIP-3{alpha} was 66.6, 68.7, and 38.7%. *, p < 0.05 and ***, p < 0. 005.

 
ELISA of MCP-1 in the culture supernatants of RSF stimulated with IL-1{beta} and TNF-{alpha} validated the stimulatory effects of these cytokines, and also suppression by p21Cip1 (Fig. 2C). The effect of IL-1{beta} was significantly suppressed by the p21Cip1expression, while that of TNF-{alpha} was unchanged (Fig. 2C). These results confirmed the biological significance of the IL-1R1 down-regulation. Furthermore, LPS stimulated RSF to increase MCP-1 production. This was suppressed by p21Cip1. Addition of IL-1ra did not attenuate the LPS-induced production of MCP-1. Thus, the suppression in this setting was also independent of IL-1 (Fig. 2C).

In accordance with the results of the preliminary DNA array analysis, MIP-3{alpha} or IL-8 protein levels were suppressed by p21Cip1 in the culture supernatants of RSF only when they were stimulated with IL-1{beta} and TNF-{alpha}. The effect of IL-1{beta} was significantly reduced by the p21Cip1 expression, while that of TNF-{alpha} was unchanged. LPS also stimulated MIP-3{alpha} production. This IL-1-independent effect was partially inhibited by p21Cip1. Similarly, the production of IL-8 was increased both by IL-1{beta} and TNF-{alpha}. The effect of IL-1{beta} but not that of TNF-{alpha} was inhibited by p21Cip1. LPS exerted a stimulatory effect on IL-8 production comparable to that of TNF-{alpha}, which was inhibited significantly by p21Cip1.

p21Cip1 suppresses expression of tissue-degrading proteinases

Northern blot analyses confirmed that p21Cip1 suppresses expression of cathepsins B and K in the unstimulated RSF, and that of MMP-1 and -3 in the stimulated RSF (Fig. 3, A–D).



View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 3. Suppression of tissue-degrading proteinase expression by p21Cip1. A and B, RSF infected with the AxCAp21 adenoviruses (p21) or control adenoviruses (control) were cultured without cytokine stimulation, and examined for cathepsins B (A) and K (B) mRNA expression by Northern blot analysis. Representative blots are shown in the upper panels. Northern blots of cathepsin B showed dual bands representing two transcripts 4.0 and 2.2 kb long (48 ). The relative levels of mRNA to those of GAPDH mRNA are shown as columns and bars, representing the mean and SD of three samples derived from different patients. Mean reduction in expression of cathepsins B and K by p21Cip1 was 47.8 and 75.0%, respectively. *, p < 0.05 and ***, p < 0.005. C and D, RSF stimulated with IL-1{beta} and TNF-{alpha} were examined for MMP-1 (C) and -3 (D) mRNA expression by Northern blot analysis. Representative blots of one of three samples are shown in the upper panels. The relative levels of mRNA of MMP-1 and -3 are shown as columns and bars, representing the mean and SD of three samples. Mean reduction in expression of MMP-1 and -3 by p21Cip1 was 78.6 and 82.6%, respectively. **, p < 0.01 and ***, p < 0.005. E and F, RSF infected with the p21Cip1 adenoviruses (open columns), and with the control adenoviruses (solid columns) were cultured without stimulation (-) or stimulated with IL-1{beta} (IL-1), TNF-{alpha} (TNF), a combination of IL-1{beta} and TNF-{alpha} (IL-1+TNF), or LPS for 24 h. MMP-1 and -3 in the culture supernatants were measured by ELISA. Representative data of two experiments are shown. Columns and bars show the mean and SD of triplicate cultures. Unstimulated RSF produced no detectable MMP-1 or -3. Mean reduction in expression of MMP-1 by p21Cip1 in IL-1, IL-1+TNF, and LPS was 70.9, 85.3, and 29.5%, respectively, and that of MMP-3 was 92.6, 71.5, and 88.3%, respectively. *, p < 0.05; **, p < 0.01; ***, p < 0.005.

 
These changes were reproduced when the concentrations of MMP-1 and -3 in the culture supernatants were determined (Fig. 3, E and F). Neither MMP was detected in the supernatants of the unstimulated RSF. MMP-1 production was increased by IL-1{beta} and TNF-{alpha}. The combination of these two cytokines had a synergistic effect. The effects of IL-1 were significantly suppressed by p21Cip1. As was the case in the cytokine production, LPS increased production of MMP-1. This effect was partially suppressed by p21Cip1. The production MMP-3 was increased by IL-1{beta} and LPS. TNF-{alpha} alone had no apparent effect but showed a synergistic effect with IL-1{beta}. Again, the effect of IL-1{beta} was suppressed by p21Cip1, and the effect of LPS was abrogated completely by p21Cip1.

p21Cip1 inhibits DNA binding activity of AP-1 and NF-{kappa}B

p21Cip1 down-regulated expression of MCP-1 and cathepsins B and K in the unstimulated RSF. Although it did not suppress expression of TLR4, it suppressed the LPS-dependent up-regulation of many inflammatory mediators. This has led us to assume that p21Cip1 should directly inhibit nonreceptor, intracellular molecules. Since promoter activity of the inflammatory mediator genes that were suppressed by p21Cip1 is controlled mostly by NF-{kappa}B and AP-1 transcription factors, we investigated the DNA binding activities of these factors in the unstimulated and LPS-stimulated RSF. Multiwell colorimetric assays to quantify DNA binding activity of the transcription factors showed that activity of AP-1 was down-regulated by p21Cip1 in the unstimulated RSF. Stimulation with LPS up-regulated activities of NF-{kappa}B p50, p65, and AP-1, all of which were down-regulated by p21Cip1 (Fig. 4A).



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 4. Suppression of AP-1 and NF-{kappa}B transcription factors by p21Cip1. RSF infected with the p21Cip1 adenoviruses (p21) or control adenoviruses (control) were cultured with or without LPS stimulation. The DNA binding activities of AP-1 and NF-{kappa}B in the adenoviruses-infected RSF relative to those of the uninfected RSF without stimulation are shown (A). Columns and bars show the mean and SD of triplicate cultures. p21Cip1 suppressed DNA binding activity of AP-1, but did not suppress that of NF-{kappa}Bp50 or p65 significantly in the unstimulated RSF. Mean reduction in expression of the AP-1 activity was 47.3%. In the LPS-stimulated RSF, p21Cip1 suppressed DNA binding activities of AP-1, NF-{kappa}Bp50, and p65. Mean reduction in expression of AP-1, NF-{kappa}Bp50, and NF-{kappa}B p65 by p21Cip1 was 47.4, 52.6, and 41.3%, respectively. *, p < 0.05. p21Cip1 in the p21Cip1-expressing RSF stimulated with LPS (p21) was coimmunoprecipitated with anti-JNK Ab ({alpha}-JNK), but not with control IgG (IgG). No precipitation was found when RSF were infected with the control viruses (control) (B). Phosphorylation of c-Jun (p-c-Jun) was suppressed in RSF infected with the p21Cip1 viruses (p21) but not in RSF infected with the control viruses (control). Reduction in expression of relative p-c-Jun levels to whole c-Jun (pan-c-Jun) was 57% (C). The results are representatives of two independent experiments.

 
It was shown that p21Cip1 associates with JNK in other type of cells, which results in reduction of the JNK enzymatic activity that activates AP-1 (16). Using anti-JNK Ab, we immunoprecipitated JNK in cell lysates of p21Cip1-expressing RSF that were stimulated with LPS. Immunoblotting of the precipitants with anti-p21Cip1Abs revealed that p21Cip1 indeed associated with JNK (Fig. 4B). Phosphorylation of c-Jun substrates showed that kinase activity of JNK was suppressed in the p21Cip1-expressing RSF (Fig. 4C). Thus, the IL-1R1-independent suppression should be at least partly due to down-regulation of these pathways.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Since the primary function of CDKIs is the inhibition of kinase activity of CDKs, the anticipated effect of the p21Cip1 expression in RSF was suppression of cell cycle progression. Indeed, RSF infected with the AxCAp21 viruses did not respond in vitro to proliferative stimuli by proinflammatory cytokines or by growth factors (4). In vivo transfer of the p21Cip1 gene into the arthritic joints of RA model rats suppressed synovial hyperplasia and cell cycle progression of the synovial fibroblasts (5).

However, the present study has revealed that p21Cip1 exerts multiple auxiliary effects: down-regulation of cytokine, chemokine, cytokine receptor, and proteinase expression critically involved in the pathology of RA. We found previously that expression of proinflammatory cytokines such as IL-1, IL-6, and TNF-{alpha} was unexpectedly inhibited in vivo in the synovial tissues treated with p21Cip1 gene transfer (4). The present report provides molecular evidence showing that p21Cip1 expression has a wide array of anti-inflammatory and bone-protective effects. Down-regulation of IL-1R1, and also IL-1R-independent inactivation of intracellular signaling pathways appeared to account for these effects (Fig. 5). Finally, these effects suggest that the p21Cip1 gene transfer might ameliorate types of inflammatory arthritides other than RA.



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 5. Multiple effects of p21Cip1 on RSF. p21Cip1 inhibited kinase activity of cyclin/CDK complexes, and down-regulated IL-1R1 expression and DNA binding activities of NF-{kappa}B and AP-1. These effects were mediated at least by binding of p21Cip1 to cyclin/CDK complexes and JNK, and resulted in inhibition of proliferation and in suppression of IL-6, -8, MCP-1, MIP-3{alpha}, cathepsins B and K, and MMP-1 and -3 expression.

 
The down-regulation of IL-6 observed in vivo was actually seen in vitro in p21Cip1-expressing RSF while the expression of IL-1 or TNF-{alpha} were not significantly modulated. It is possible that the decreased expression of IL-1 and TNF-{alpha} in the synovial tissues was due to their down-regulation in the synovial macrophages. The macrophages are the primary source of these cytokines and, together with synovial fibroblasts, were targeted by the intraarticular adenoviral gene transfer (15, 17). Alternatively, the down-regulation of IL-1 and TNF-{alpha} might result from en bloc suppression of the inflammatory cytokine/chemokine network, multiple members of which were suppressed by p21Cip1.

IL-6, in the rheumatoid synovial tissues, derives from the activated synovial macrophages and fibroblasts, and stimulates local osteoclasts to resorb the bone matrices in the affected joints. It also stimulates T and B lymphocytes. This has made this cytokine the target of a new biological reagent that is currently in clinical trials (18, 19). IL-8 produced by the activated synovial cells contributes to recruitment of neutrophils and T lymphocytes and to neovascularization in the rheumatoid tissues (20). The other chemokines, MCP-1 and MIP-3{alpha}, both evoke migration and activation of lymphocytes and macrophages in the rheumatoid synovial tissues (21, 22). Blockage of MCP-1 receptor was effective in treating an animal model of RA (23). Thus, the cytokines and chemokines down-regulated by p21Cip1 all play crucial roles in the rheumatoid inflammation.

Tissue degrading enzymes, such as MMPs and cathepsins, are abundantly expressed in rheumatoid synovial tissues. MMP-1 and -3 degrade collagen and proteoglycans that compose the matrices of bone and cartilage. In addition, it has been proposed that MMP-3 cleaves many proMMPs in the initiation of the proteinase cascade in rheumatoid joints (2). Treatment to inhibit MMP-1 production prevented bone destruction in adjuvant arthritis of rats (24). Cathepsin B might contribute to rheumatoid joint damage by degrading collagen (25, 26, 27). Cathepsin K is not only expressed by osteoclasts, but also by synovial fibroblasts, contributing to bone destruction in the rheumatoid joints (28, 29). Down-regulation of these proteinases in the p21Cip1-expressing RSF was consistent with the remarkable inhibition of bone and cartilage degeneration observed in the p21Cip1 gene therapy.

Expression of IL-1R1 was suppressed by p21Cip1. IL-1 is one of the critical cytokines in the rheumatoid inflammation. It enhances migration of inflammatory cells into the synovial tissues and stimulates production of cytokines, chemokines and MMPs (15). Its blockade by an antagonist ameliorates RA (30, 31, 32). We saw that IL-1-triggered promotion of IL-6, IL-8, MCP-1, MIP-3{alpha}, and MMP-1 and -3 release from RSF was significantly suppressed by p21Cip1. These results argue that down-regulation of IL-1R1 must be functionally relevant to the therapeutic effects.

MCP-1 and cathepsin B and K expression was suppressed even when RSF were not stimulated. Conventional ELISA detected no IL-1 in the culture supernatant of the unstimulated RSF. The blockade of IL-1 with IL-1ra did not affect the results. Thus, the suppression observed in the unstimulated RSF was not mediated by the down-regulation of IL-1R1. LPS also up-regulated MCP-1 expression, and induced expression of IL-6, IL-8, MIP-3{alpha}, and MMP-1 and -3. This was not accompanied by reduced expression of TLR4, which is a signaling receptor for LPS. The LPS-stimulated RSF under these conditions did not release a detectable level of IL-1 into the culture supernatants, and IL-1 blockade by IL-1ra did not alter the results. Thus, inhibition of the inflammatory molecule expression could be at least partly due to modulation of intracellular pathways that are independent of IL-1R1. IL-1 and TNF-{alpha} have distinct pathways in the afferent arm of the signal transduction whereas IL-1 and LPS share a part of the signal transduction molecules (33). Presumably, this difference should account for the distinct effect of p21Cip1 on TNF-{alpha} and LPS stimulation.

The IL-1R-independent suppression was accompanied by reduced activity of NF-{kappa}B and AP-1. In the rheumatoid synovial tissues these factors activate transcription of various inflammatory cytokines, chemokines, and proteinases including those analyzed in the present studies (17, 24, 34, 35, 36, 37, 38, 39, 40, 41, 42). In agreement with our observation, constitutive expression of MCP-1 by mesangial cells required activation of AP-1 (43). Notably, the promoter of the IL-1R1 gene has two AP-1-like binding sites (44). This suggests that the repressed activity of AP-1 might contribute to the down-regulation of IL-1R1.

Depending on the cell type, p21Cip1 binds to a variety of intracellular proteins other than CDKs. These include signal transduction molecules and transcription factors (7). We have shown that p21Cip1 indeed binds to JNK and suppresses its kinase activity in RSF. It is known that JNK could activate NF-{kappa}B by degrading I{kappa}-B (45, 46). Thus, interaction of p21Cip1 with mitogen-activated protein kinase might account for the reduced activity of AP-1 and NF-{kappa}B.

Chang et al. (47) used the DNA array technique to study effects of p21Cip1 on gene expression in HT1080 human sarcoma cell line; they observed that genes related to senescence or age-related diseases were induced. We have shown here that p21Cip1 expression modulates the expression of genes related to inflammation. Although, Chang et al. found up-regulation of the cathepsin B gene in HT1080 cells, the same gene was down-regulated in RSF. It is probable that the effects of p21Cip1 depend on the cell types.

In conclusions, p21Cip1 gene transfer to the RSF regulated expression of various genes. Its effects include down-regulation of cytokine, chemokine, cytokine receptor and proteinase expression. Down-regulation of IL-1R1, as well as inactivation of intracellular signaling pathways appeared to account for these effects. These collateral effects observed in the p21Cip1 gene transfer suggest new links between CDKIs and immunological effector molecules.


   Acknowledgments
 
We thank Drs. T. Muneta, Y. Kuga, and J. Hasegawa for providing synovial samples; Drs. N. Terada and M. Ikeda for providing adenoviruses; Drs. R. Koike, H. Hagiyama, T. Nanki, and H. Nishitoh for their technical support and advice; and also Dr. N. Nishimura at Genetic Laboratory (Sapporo, Japan) performing DNA array experiments. We are grateful to Dr. T. Page for reviewing the manuscript.


   Footnotes
 
1 This work was supported by grants from the Japanese Ministry of Health, Labor and Welfare, from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Japan, and from the Kato Memorial Bioscience Foundation. Back

2 Address correspondence and reprint requests to Dr. Hitoshi Kohsaka, Bioregulatory Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail address: kohsaka.rheu{at}tmd.ac.jp Back

3 Abbreviations used in this paper: RA, rheumatoid arthritis; CDKI, cyclin-dependent kinase inhibitor; CDK, cyclin/cyclin-dependent kinase; RSF, rheumatoid synovial fibroblast; IL-1ra, IL-1R antagonist; JNK, c-Jun N-terminal kinase; IL-1R1, type I IL-1R; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinase; MIP, macrophage inflammatory protein; TLR, Toll-like receptor. Back

Received for publication December 30, 2002. Accepted for publication August 20, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Hale, L., B. Haynes. 1997. Pathology of rheumatoid arthritis and associated disorders. W. Koopman, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology 993. Williams & Wilkins, Baltimore.
  2. Okada, Y.. 2001. Proteinases and matrix degradation. S. Ruddy, and E. D. Harris, Jr., and C. B. Sledge, Jr., eds. In Kelly’s Textbook of Rheumatology Vol. 1:55. W. B. Saunders, Philadelphia.
  3. Taniguchi, K., H. Kohsaka, N. Inoue, Y. Terada, H. Ito, K. Hirokawa, N. Miyasaka. 1999. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat. Med. 5:760.[Medline]
  4. Nasu, K., H. Kohsaka, Y. Nonomura, Y. Terada, H. Ito, K. Hirokawa, N. Miyasaka. 2000. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J. Immunol. 165:7246.[Abstract/Free Full Text]
  5. Nonomura, Y., H. Kohsaka, K. Nasu, Y. Terada, M. Ikeda, N. Miyasaka. 2001. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21Cip1 gene into the joints. Int. Immunol. 13:723.[Abstract/Free Full Text]
  6. Sherr, C. J., J. M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501.[Free Full Text]
  7. Dotto, G. P.. 2000. p21WAF1/Cip1: more than a break to the cell cycle?. Acta Biochim. Biophys. 1471:M43.
  8. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315.[Medline]
  9. Terada, Y., T. Yamada, O. Nakashima, M. Tamamori, H. Ito, S. Sasaki, F. Marumo. 1997. Overexpression of cell cycle inhibitors (p16INK4 and p21Cip1) and cyclin D1 using adenovirus vectors regulates proliferation of rat mesangial cells. J. Am. Soc. Nephrol. 8:51.[Abstract]
  10. Kumagai, T., T. Miki, M. Kikuchi, T. Fukuda, N. Miyasaka, R. Kamiyama, S. Hirosawa. 1999. The proto-oncogene Bcl6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene 18:467.[Medline]
  11. Sadouk, M. B., J. P. Pelletier, G. Tardif, K. Kiansa, J. M. Cloutier, J. Martel-Pelletier. 1995. Human synovial fibroblasts coexpress IL-1R type I and type II mRNA: the increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab. Invest. 73:347.[Medline]
  12. Moore, B. A., S. Aznavoorian, J. A. Engler, L. J. Windsor. 2000. Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts. Acta Biochim. Biophys. 1502:307.
  13. Patel, R., B. Bartosch, J. L. Blank. 1998. p21WAF1 is dynamically associated with JNK in human T lymphocytes during cell cycle progression. J. Cell Sci. 111:2247.[Abstract]
  14. Renard, P., I. Ernest, A. Houbion, M. Art, H. Le Calvez, M. Raes, J. Remacle. 2001. Development of a sensitive multi-well colorimetric assay for active NF-{kappa}B. Nucleic Acids Res. 29:E21.
  15. Feldmann, M., F. M. Brennan, R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.[Medline]
  16. Shim, J., H. Lee, J. Park, H. Kim, E. J. Choi. 1996. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381:804.[Medline]
  17. Bondeson, J., B. Foxwell, F. Brennan, M. Feldmann. 1999. Defining therapeutic targets by using adenovirus: blocking NF-{kappa}B inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl. Acad. Sci. USA 96:5668.[Abstract/Free Full Text]
  18. Wendling, D., E. Racadot, J. Wijdenes. 1993. Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J. Rheumatol. 20:259.[Medline]
  19. Yoshizaki, K., N. Nishimoto, M. Mihara, T. Kishimoto. 1998. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol. 20:247.[Medline]
  20. Koch, A. E., M. V. Volin, J. M. Woods, S. L. Kunkel, M. A. Connors, L. A. Harlow, D. C. Woodruff, M. D. Burdick, R. M. Strieter. 2001. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum. 44:31.[Medline]
  21. Koch, A. E., S. L. Kunkel, L. A. Harlow, B. Johnson, H. L. Evanoff, G. K. Haines, M. D. Burdick, R. M. Pope, R. M. Strieter. 1992. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 90:772.
  22. Chabaud, M., G. Page, P. Miossec. 2001. Enhancing effect of IL-1, IL-17, and TNF-{alpha} on macrophage inflammatory protein-3{alpha} production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J. Immunol. 167:6015.[Abstract/Free Full Text]
  23. Gong, J. H., L. G. Ratkay, J. D. Waterfield, I. Clark-Lewis. 1997. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186:131.[Abstract/Free Full Text]
  24. Han, Z., D. L. Boyle, L. Chang, B. Bennett, M. Karin, L. Yang, A. M. Manning, G. S. Firestein. 2001. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108:73.[Medline]
  25. Trabandt, A., R. E. Gay, H. G. Fassbender, S. Gay. 1991. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum. 34:1444.[Medline]
  26. Cunnane, G., O. FitzGerald, K. M. Hummel, R. E. Gay, S. Gay, B. Bresnihan. 1999. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford) 38:34.
  27. Turk, B., D. Turk, V. Turk. 2000. Lysosomal cysteine proteases: more than scavengers. Acta Biochim. Biophys. 1477:98.
  28. Kaneko, M., T. Tomita, T. Nakase, Y. Ohsawa, H. Seki, E. Takeuchi, H. Takano, K. Shi, K. Takahi, E. Kominami, et al 2001. Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. Rheumatology (Oxford) 40:247.
  29. Hou, W. S., W. Li, G. Keyszer, E. Weber, R. Levy, M. J. Klein, E. M. Gravallese, S. R. Goldring, D. Bromme. 2002. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 46:663.[Medline]
  30. Dayer, J. M., U. Feige, C. K. Edwards, III, D. Burger. 2001. Anti-interleukin-1 therapy in rheumatic diseases. Curr. Opin. Rheumatol. 13:170.[Medline]
  31. Bresnihan, B., J. M. Alvaro-Gracia, M. Cobby, M. Doherty, Z. Domljan, P. Emery, G. Nuki, K. Pavelka, R. Rau, B. Rozman, et al 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196.[Medline]
  32. Jiang, Y., H. K. Genant, I. Watt, M. Cobby, B. Bresnihan, R. Aitchison, D. McCabe. 2000. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human IL-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43:1001.[Medline]
  33. Beutler, B.. 2000. Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. 12:20.[Medline]
  34. Fujisawa, K., H. Aono, T. Hasunuma, K. Yamamoto, S. Mita, K. Nishioka. 1996. Activation of transcription factor NF-{kappa}B in human synovial cells in response to TNF-{alpha}. Arthritis Rheum. 39:197.[Medline]
  35. Asahara, H., K. Fujisawa, T. Kobata, T. Hasunuma, T. Maeda, M. Asanuma, N. Ogawa, H. Inoue, T. Sumida, K. Nishioka. 1997. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum. 40:912.[Medline]
  36. Han, Z., D. L. Boyle, A. M. Manning, G. S. Firestein. 1998. AP-1 and NF-{kappa}B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28:197.[Medline]
  37. Aupperle, K. R., B. L. Bennett, D. L. Boyle, P. P. Tak, A. M. Manning, G. S. Firestein. 1999. NF-{kappa}B regulation by I{kappa}B kinase in primary fibroblast-like synoviocytes. J. Immunol. 163:427.[Abstract/Free Full Text]
  38. Georganas, C., H. Liu, H. Perlman, A. Hoffmann, B. Thimmapaya, R. M. Pope. 2000. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-{kappa}B but not C/EBP{beta} or c-Jun. J. Immunol. 165:7199.[Abstract/Free Full Text]
  39. Mengshol, J. A., K. S. Mix, C. E. Brinckerhoff. 2002. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull’s-eye or missing the mark?. Arthritis Rheum. 46:13.[Medline]
  40. Auron, P. E., A. C. Webb. 1994. Interleukin-1: a gene expression system regulated at multiple levels. Eur. Cytokine Netw. 5:573.[Medline]
  41. Roebuck, K. A.. 1999. Regulation of interleukin-8 gene expression. J. Interferon Cytokine Res. 19:429.[Medline]
  42. Gelb, B. D., G. P. Shi, M. Heller, S. Weremowicz, C. Morton, R. J. Desnick, H. A. Chapman. 1997. Structure and chromosomal assignment of the human cathepsin K gene. Genomics 41:258.[Medline]
  43. Lucio-Cazana, J., K. Nakayama, Q. Xu, T. Konta, V. Moreno-Manzano, A. Furusu, M. Kitamura. 2001. Suppression of constitutive but not IL-1{beta}-inducible expression of monocyte chemoattractant protein-1 in mesangial cells by retinoic acids: intervention in the AP-1 pathway. J. Am. Soc. Nephrol. 12:688.[Abstract/Free Full Text]
  44. Ye, K., C. A. Dinarello, B. D. Clark. 1993. Identification of the promoter region of human interleukin-1 type I receptor gene: multiple initiation sites, high G+C content, and constitutive expression. Proc. Natl. Acad. Sci. USA 90:2295.[Abstract/Free Full Text]
  45. Spiegelman, V. S., P. Stavropoulos, E. Latres, M. Pagano, Z. Ronai, T. J. Slaga, S. Y. Fuchs. 2001. Induction of {beta}-transducin repeat-containing protein by JNK signaling and its role in the activation of NF-{kappa}B. J. Biol. Chem. 276:27152.[Abstract/Free Full Text]
  46. Das, K. C.. 2001. c-Jun NH2-terminal kinase-mediated redox-dependent degradation of I{kappa}B: role of thioredoxin in NF-{kappa}B activation. J. Biol. Chem. 276:4662.[Abstract/Free Full Text]
  47. Chang, B. D., K. Watanabe, E. V. Broude, J. Fang, J. C. Poole, T. V. Kalinichenko, I. B. Roninson. 2000. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. USA 97:4291.[Abstract/Free Full Text]
  48. DiPaolo, B. R., R. J. Pignolo, V. J. Cristofalo. 1992. Overexpression of the two-chain form of cathepsin B in senescent WI-38 cells. Exp. Cell Res. 201:500.[Medline]

Related articles in The JI:

IN THIS ISSUE

The JI 2003 171: 4471-4472. [Full Text]  



This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Sekine, T. Sugihara, S. Miyake, H. Hirai, M. Yoshida, N. Miyasaka, and H. Kohsaka
Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors
J. Immunol., February 1, 2008; 180(3): 1954 - 1961.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. C. Scatizzi, J. Hutcheson, E. Bickel, J. M. Woods, K. Klosowska, T. L. Moore, G. K. Haines III, and H. Perlman
p21Cip1 Is Required for the Development of Monocytes and Their Response to Serum Transfer-induced Arthritis
Am. J. Pathol., May 1, 2006; 168(5): 1531 - 1541.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A Radbruch and A Thiel
Cell therapy for autoimmune diseases: does it have a future?
Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii96 - ii101.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nonomura, Y.
Right arrow Articles by Miyasaka, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nonomura, Y.
Right arrow Articles by Miyasaka, N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS